Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation

Minh Phuong Vu; Thi Van Oanh Kieu; Hoang Vu

doi:10.1016/j.lrr.2023.100368

Consolidation and maintenance therapy with bortezomib for Vietnamese patients with multiple myeloma after autologous transplantation

Leuk Res Rep. 2023 Mar 21:19:100368. doi: 10.1016/j.lrr.2023.100368. eCollection 2023.

Authors

Minh Phuong Vu^{1

2}, Thi Van Oanh Kieu², Hoang Vu²

Affiliations

¹ Department of Hematology, Hanoi Medical University, 1 Ton That Tung Street, Hanoi, Vietnam.
² Center for Hematology and Blood Transfusion, Bach Mai Hospital, 78 Giai Phong Road, Hanoi, Vietnam.

Abstract

Thirty patients with newly diagnosed symtomatic MM (multiple myeloma) received ASCT (autologous stem cell transplantation) and two cycles of bortezomib-cyclophosphamide-dexamethasone as consolidation treatment followed by maintenance of bortezomib for 24 months. 16 patients achieved complete response (CR) after ASCT, and two more patients achieved CR after consolidation therapy. At 92 months of follow-up, the median OS was 69.5 months, the median PFS was 38.5 months. OS and PFS in the high-risk group were shorter than in the standard-risk group with a statistically significant difference (p = 0.028, 0.049; respectively). Post-ASCT consolidation and maintenance therapy using bortezomib were effective in patients with MM.

Keywords: Consolidation therapy, Maintenance therapy; Multiple myeloma; Post- ASCT.

Publication types

Review